- Home
- TNGX vs TERN Comparison
TNGX vs TERN Comparison
Compare TNGX & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- TERN
- Stock Information
- Founded
- TNGX 2014
- TERN 2017
- Country
- TNGX United States
- TERN United States
- Employees
- TNGX 140
- TERN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- TERN Health Care
- Exchange
- TNGX Nasdaq
- TERN Nasdaq
- Market Cap
- TNGX 747.9M
- TERN 811.4M
- IPO Year
- TNGX N/A
- TERN 2021
- Fundamental
- Price
- TNGX $6.98
- TERN $8.27
- Analyst Decision
- TNGX Strong Buy
- TERN Strong Buy
- Analyst Count
- TNGX 8
- TERN 5
- Target Price
- TNGX $15.14
- TERN $15.90
- AVG Volume (30 Days)
- TNGX 1.3M
- TERN 3.7M
- Earning Date
- TNGX 11-06-2024
- TERN 11-12-2024
- Dividend Yield
- TNGX N/A
- TERN N/A
- EPS Growth
- TNGX N/A
- TERN N/A
- EPS
- TNGX N/A
- TERN N/A
- Revenue
- TNGX $42,509,000.00
- TERN N/A
- Revenue This Year
- TNGX $18.15
- TERN N/A
- Revenue Next Year
- TNGX N/A
- TERN N/A
- P/E Ratio
- TNGX N/A
- TERN N/A
- Revenue Growth
- TNGX 26.16
- TERN N/A
- 52 Week Low
- TNGX $5.15
- TERN $3.26
- 52 Week High
- TNGX $13.01
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- TNGX 33.20
- TERN 44.79
- Support Level
- TNGX $6.72
- TERN $7.82
- Resistance Level
- TNGX $7.78
- TERN $9.00
- Average True Range (ATR)
- TNGX 0.56
- TERN 0.58
- MACD
- TNGX -0.11
- TERN -0.22
- Stochastic Oscillator
- TNGX 8.48
- TERN 15.63
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.